openFDA
Cure8 regulatory brief
Why This Matters
This FDA label update affects people with IBD because tofacitinib is an approved JAK inhibitor for moderately to severely active ulcerative colitis and carries serious safety warnings that may influence treatment choices and monitoring.
Who Should Pay Attention
Adult patients with ulcerative colitis or other inflammatory diseases on or considering tofacitinib; prescribing clinicians; caregivers concerned about drug safety.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The FDA label update posted on DailyMed is a regulatory record for tofacitinib (extended-release/XELJANZ) describing approved indications, boxed warnings, and limitations of use.
It lists indications including moderately to severely active ulcerative colitis and other inflammatory diseases, and includes a boxed warning about serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.
The label advises testing for latent TB before and during therapy and notes risks with concomitant immunosuppressants. Read the label sections on Indications, Boxed Warning, and Limitations of Use for specifics about recommended combinations to avoid and dosing cautions.
The update is a primary source from the FDA (DailyMed) and represents official prescribing information rather than a research study.
If you use or are considering tofacitinib, discuss this updated label and its boxed warnings with your clinician; they can interpret risks (for example related to age, smoking, or cardiovascular risk factors) and consider alternative therapies or monitoring plans.
Keep In Mind
This is an official prescribing-information update (regulatory record) from DailyMed/FDA; it reflects approved labeling and safety communications rather than new trial findings. Discuss implications with your clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorScieGen Pharmaceuticals, INC.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 21, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
DailyMed label update for RINVOQ
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...
TOFACITINIB FDA label update (2026-07-06)
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...